Drug Trial Radar · NCT01490450
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
Last checked: Nov 20, 2026Latest source record: Nov 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
165
Actual
Start
Dec 2011
Primary completion
Jun 2013
Study completion Jun 2015
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic Disease modifying anti-rheumatic drugs (DMARDs).
Conditions
- Arthritis, Psoriatic
Interventions
Placebo matching BMS-945429Biological
Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
BMS-945429Biological
Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
BMS-945429Biological
Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
BMS-945429Biological
Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20)Time frame: At 16 weeks
Locations
49 sites in 13 countries. Site status is shown where the registry gives one.
San Diego Arthritis Medical Clinic
San Diego, California
Denver Arthritis Clinic
Denver, Colorado
New England Research Associates, Llc
Trumbull, Connecticut
Sarasota Arthritis Research Center
Sarasota, Florida
Arthritis Associates Of Mississippi
Jackson, Mississippi
Box Arthritis And Rheumatology Of The Carolinas, Pllc
Charlotte, North Carolina
Health Research Of Oklahoma
Oklahoma City, Oklahoma
East Penn Rheumatology Associates, P.C.
Bethlehem, Pennsylvania
Local Institution
San Miguel de Tucumán, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Cairns, Queensland, Australia
Local Institution
Maroochydore, Queensland, Australia
Local Institution
Woodville, South Australia, Australia
Local Institution
Shenton Park, Western Australia, Australia
Manitoba Clinic
Winnipeg, Manitoba, Canada
Local Institution
Montreal, Quebec, Canada
Centre De Rhumatologie De L Est Du Quebec
Rimouski, Quebec, Canada
Centre De Recherche Musculo-Squelettique
Trois-Rivières, Quebec, Canada
Local Institution
Pardubice, Czechia
Local Institution
Prague, Czechia
Local Institution
Bad Nauheim, Germany
Local Institution
Erlangen, Germany
Local Institution
Planegg, Germany
Local Institution
Budapest, Hungary
Local Institution
Budapest, Hungary
Local Institution
Debrecen, Hungary
Local Institution
Veszprém, Hungary
Local Institution
Florence, Italy
Local Institution
Naples, Italy
Local Institution
México, Aguascalientes, Mexico
Local Institution
Zapopan, Jalisco, Mexico
Local Institution
Monterrey, Nuevo León, Mexico
Local Institution
Bialystok, Poland
Local Institution
Dąbrówka, Poland
Local Institution
Elblag, Poland
Local Institution
Poznan, Poland
Local Institution
Warsaw, Poland
Local Institution
Moscow, Russia
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.